by Clinical Neuropsychologist | Sunday, October 6, 2024 | Dementia
Abstract INTRODUCTION We evaluated the efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia (AAD) in Japanese patients. METHODS This was a phase 2/3 multicenter, randomized, double-blind, placebo-controlled, parallel-group...
by Clinical Neuropsychologist | Sunday, October 6, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Nilton Custodio, Ricardo Allegri, Francisco Lopera, Paulo...
by Clinical Neuropsychologist | Sunday, October 6, 2024 | Dementia
Abstract INTRODUCTION People with neurodegenerative disorders (ND) frequently face diagnostic delay and misdiagnosis. We investigated blood and cerebrospinal fluid (CSF) neurofilament light chain (NfL) to distinguish ND from primary psychiatric disorders (PPD), a...
by Clinical Neuropsychologist | Sunday, October 6, 2024 | Dementia
Abstract The Alzheimer’s Disease Neuroimaging Initiative (ADNI) has fostered collaboration among researchers around the world, catalyzing innovation and accelerating progress in the field. In Latin America, this initiative advanced the validation and development...
by Clinical Neuropsychologist | Sunday, October 6, 2024 | Dementia
Abstract INTRODUCTION It is unclear how early neuronal deficits occur in tauopathies, if these are associated with changes in neuronal network activity, and if they can be alleviated with therapies. METHODS To address this, we performed in vivo two-photon Ca2+ imaging...
